## TABLE OF CONTENTS

### HIGHLIGHTS

2233  Selected Articles from This Issue

### MCT FIRST DISCLOSURES

2235  Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer

### REVIEW

2245  Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer

### SMALL MOLECULE THERAPEUTICS

2256  The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade

2267  An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells

2278  Synthetic Lethal Metabolic Targeting of Androgen-Deprived Prostate Cancer Cells with Metformin

### LARGE MOLECULE THERAPEUTICS

2288  CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation

2298  Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

2308  Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma

2319  Menin-mediated Repression of Glycolysis in Combination with Autophagy Protects Colon Cancer Against Small-molecule EGFR Inhibitors

2330  LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia

2340  Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function
CANCER BIOLOGY AND TRANSLATIONAL STUDIES

2363 Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)

2371 Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction
Ivana Spasevska, Eva Laure Matera, Kamel Chettab, Jade Ville, Marie Potier-Cartereau, Lars Petter Jordheim, Catherine Thieblemont, Denis Sahin, Christian Klein, and Charles Dumontet

2382 

2396 Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer
Mark Seungwook Kim, Shaolin Ma, Anca Chelariu-Raicu, Carola Leuschner, Hector W. Allila, Sanghoon Lee, Robert L. Coleman, and Anil K. Sood

ABOUT THE COVER

In this issue of Molecular Cancer Therapeutics, Jin and colleagues describe the discovery and mechanism of novel anti-CD73 antibody (Hu001) and CD73-ADC (Hu001-MMAE). High CD73 staining was found in lung cancer epithelial tumor cells and stromal cells in tumor microenvironment, pictured on our cover. The anti-tumor efficacy of Hu001 required both the Fc-dependent cell-mediated cytotoxicity and a multifaceted remodeling in the tumor immune microenvironment. The novel Hu001-MMAE elicited dramatic dual benefits in killing CD73-high tumors while simultaneously promoting the effector function in T lymphocytes and dendritic cells. Read the full article on page 2340.